N/A
N=139
Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection in Adult Women
Recurrent Urinary Tract Infection in Adult Women
Bottom Line
View on ClinicalTrials.gov: NCT03366077 ↗Enrolled (actual)
139
Serious AEs
2.2%
Results posted
Sep 2025
Primary outcome: Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of unique UTIs during study
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Probiotic (Dietary_supplement)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- BioGaia AB
- Primary completion
- Jul 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. |
1.2; 1.3 | — |
| SECONDARY To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the -Frequency of Confirmed UTI -Time to First Relapse of UTI. -Relapse Rate -Assess the Tolerability |
— | — |
Summary
Urinary tract infections (UTIs) are the most common bacterial infections in women, with about 50% of women experiencing at least one UTI in their lifetime.
The main pharmacological treatments of cystitis usually involve the use of antibiotics, in particular quinolones (such as ciprofloxacin and levofloxacin), fosfomycin, second-generation and third-generation cephalosporins, and b-lactam antibiotics associated with b-lactamase inhibitors.
Eligibility Criteria
Inclusion Criteria
- Willing and able to give informed consent for participation in the study.
- Woman aged 18-50 years old at screening.
- BMI ≥18 at screening.
- Currently on antibiotic treatment for UTI, at the time of screening. Antibiotic treatment must stop within three days prior to first IP dose.
- Recurrent UTI defined as at least two UTIs during the last six months or at least three UTIs during the last 12 months, according to information given by the subject.
- Able and willing to comply with the restrictions defined for the the study period (see Section 10.6).
- Access to Bank ID and ability to use the e-health platform (i.e. Internet access).
- Ability to understand and comply with the requirements of the study, as judged by the Investigator.
Exclusion Criteria
- Postmenopausal (defined as 12 months of amenorrhoea).
- Pregnant or breastfeeding.
- Planning to become pregnant during the study.
- Irregular menstruations combined with perimenopausal symptoms.
- Known hypersensitivity or allergy to any of the components of the test product, or to the comparator (placebo).
- Use of spermicide contraceptives including spermicidal condom within three days prior to first IP dose.
- History of complicated cystitis, urgency incontinence, recent pyelonephritis, urological and/or gynaecologist abnormalities, immunocompromised, as judged by the Investigator.
- Unstable bowel disorder such as diarrhoea, Crohn's disease, ulcerative colitis.
-
Data sourced from ClinicalTrials.gov (NCT03366077). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.